Department of Chemical, Biological, Pharmaceuticals and Environmental Sciences, University of Messina, Viale Stagno d'Alcontres, 98166 Messina, Italy.
Department of Biochemical, Dental, Morphological and Functional Imaging, University of Messina, Via Consolare Valeria, 98125 Messina, Italy.
Int J Mol Sci. 2024 Oct 30;25(21):11661. doi: 10.3390/ijms252111661.
Neurodegenerative diseases (NDDs) are currently the most widespread neuronal pathologies in the world. Among these, the most widespread are Alzheimer's disease (AD), dementia, Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and Huntington's disease (HD)-all characterized by a progressive loss of neurons in specific regions of the brain leading to varied clinical symptoms. At the basis of neurodegenerative diseases, an emerging role is played by genetic mutations in the leucine-rich repeat kinase 2 (LRRK2) gene that cause increased LRRK2 activity with consequent alteration of neuronal autophagy pathways. LRRK2 kinase activity requires GTPase activity which functions independently of kinase activity and is required for neurotoxicity and to potentiate neuronal death. Important in the neurodegeneration process is the upregulation of casein kinase (CK), which causes the alteration of the AMPK pathway by enhancing the phosphorylation of α-synuclein and huntingtin proteins, known to be involved in PD and HD, and increasing the accumulation of the amyloid-β protein (Aβ) for AD. Recent research has identified CK of the kinases upstream of LRRK2 as a regulator of the stability of the LRRK2 protein. Based on this evidence, this review aims to understand the direct involvement of individual kinases in NDDs and how their crosstalk may impact the pathogenesis and early onset of neurodegenerative diseases.
神经退行性疾病(NDDs)是目前世界上最广泛的神经元病理学。其中,最广泛的是阿尔茨海默病(AD)、痴呆、帕金森病(PD)、肌萎缩侧索硬化症(ALS)和亨廷顿病(HD)——所有这些疾病都以大脑特定区域神经元的进行性丧失为特征,导致各种临床症状。在神经退行性疾病的基础上,亮氨酸丰富重复激酶 2(LRRK2)基因中的遗传突变起着新兴作用,导致 LRRK2 活性增加,进而改变神经元自噬途径。LRRK2 激酶活性需要 GTPase 活性,它独立于激酶活性起作用,是神经毒性和增强神经元死亡所必需的。在神经变性过程中重要的是酪蛋白激酶(CK)的上调,它通过增强α-突触核蛋白和亨廷顿蛋白的磷酸化来改变 AMPK 途径,已知这些蛋白参与 PD 和 HD,并增加淀粉样β蛋白(Aβ)的积累用于 AD。最近的研究已经确定 LRRK2 上游的激酶 CK 是 LRRK2 蛋白稳定性的调节剂。基于这一证据,本综述旨在了解单个激酶在 NDDs 中的直接参与以及它们的串扰如何影响神经退行性疾病的发病机制和早期发病。